Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis.

Yan YeMei LiuLonghai TangFang DuYuanhua LiuPei HaoQiong FuQiang GuoQingran YanXiaoming ZhangChunde Bao

Published in: Arthritis research & therapy (2019)

Iguratimod inhibits ASC differentiation both in vitro and in RA patients. Our study suggests that PKC/EGR1 axis, rather than COX-2, is critically involved in the inhibitory effect by iguratimod on human ASC differentiation. Iguratimod could have a broader application to treat B cell-related autoimmune diseases in clinics.

Keyphrases

end stage renal disease
endothelial cells
ejection fraction
newly diagnosed
chronic kidney disease
primary care
rheumatoid arthritis
peritoneal dialysis
prognostic factors
nlrp inflammasome
patient reported outcomes
idiopathic pulmonary fibrosis